Silvercrest Asset Management Group LLC Alnylam Pharmaceuticals, Inc. Transaction History
Silvercrest Asset Management Group LLC
- $14.6 Billion
- Q2 2025
A detailed history of Silvercrest Asset Management Group LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 10,251 shares of ALNY stock, worth $4.86 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
10,251
Previous 9,821
4.38%
Holding current value
$4.86 Million
Previous $2.65 Million
26.07%
% of portfolio
0.02%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding ALNY
# of Institutions
785Shares Held
115MCall Options Held
584KPut Options Held
648K-
Capital World Investors Los Angeles, CA16.8MShares$7.97 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$6.3 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.53 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.41 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.28MShares$2.03 Billion0.88% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $58.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...